METHOD FOR PREDICTION OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C AND RECEIVING COMBINATION ANTIVIRAL THERAPY Russian patent published in 2015 - IPC A61B8/00 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention can be used to predict thrombocytopenia in the patients suffering chronic hepatitis C (CHC) as a result of a combination antiviral therapy (CAT). Before the CAT starts, viral load (VL, IU/ml) is determined in the CHC patients. A fibrosis level is shown by indirect liver fibroelastography (F, kPa). A pre-CAT blood thrombocyte count is determined (Thr_initial, x10⁹/l). The received data are used to derive a predicted minimum blood thrombocyte count (Thr_min, x10⁹/l) by multiple linear regression. If Thr_min≤150.0x10⁹/l, the risk of thrombocytopenia progression in the CHC patients receiving the CAT. If Thr_min falls within the range from 75.0x10⁹/l to 150.0x10⁹/l enables supposing progression of mild thrombocytopenia; Thr_min from 50.0x10⁹/l to 75.0x10⁹/l shows moderate thrombocytopenia, and Thr_min<50.0x10⁹/l - severe thrombocytopenia.

EFFECT: method enables accurate, fast and simple prediction of thrombocytopenia progression by the integrated assessment of the most important factors of thrombocytopenia.

1 tbl, 2 ex